HIGHFDA DRUG

Harbin Jixianglong Biotech Semaglutide Rx Compounding Recall 2026 — 6 Packaging Sizes

Harbin Jixianglong Biotech Co. recalled Semaglutide for Rx compounding use nationwide in the United States. The recall cites CGMP deviations and failure to complete endotoxin validation before distribution. Healthcare providers and patients should stop using the product immediately and contact the company or a healthcare provider for guidance via email.

Official notice
Harbin Jixianglong Biotech Co.Health & Personal CareDrugs & MedicationsBatch CP-030-20250911Mfg Date: Sep 25, 2025Retest Date: Sep 24, 2027

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DRUG
Recall date
February 13, 2026
Status
ACTIVE
Severity
7/10

Quick Facts at a Glance

Recall Date
February 13, 2026
Hazard Level
HIGH
Brand
Harbin Jixianglong Biotech Co.
Category
Health & Personal Care
Sold At
Unknown
Geographic Scope
1 states
At-Risk Groups
GENERAL

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
Harbin Jixianglong Biotech Co.
Product type
Semaglutide for Rx compounding
Model numbers
Batch CP-030-20250911, Mfg Date: Sep 25, 2025, Retest Date: Sep 24, 2027, 2025, 2027
Sold at
Unknown
Where affected
ALL

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    February 13, 2026

  2. Reported by FDA DRUG

    March 11, 2026

  3. RecallRadar source check

    March 18, 2026

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Harbin Jixianglong Biotech Co., Ltd. or your healthcare provider for guidance. Notification method: E-Mail

About This Product

Semaglutide for Rx compounding is used to prepare customized pharmaceutical products for patients under medical supervision.

Why This Is Dangerous

CGMP deviations and lack of validated endotoxin testing raise risk of contaminated injectable product and possible infection.

Industry Context

This recall is not described as part of a broader industry pattern.

Real-World Impact

Potential endotoxin exposure could lead to severe infection in patients requiring medical treatment.

Practical Guidance

How to identify if yours is affected

  1. Check Lot: CP-030-20250911.
  2. Confirm manufacturing date: Sep 25, 2025.
  3. Check retest date: Sep 24, 2027.

Where to find product info

FDA enforcement recall page for D-0380-2026; recall notice details.

What timeline to expect

Not specified by the recall notice; use FDA guidance and company contact for updates.

If the manufacturer is unresponsive

  • Escalate to FDA recall contact channels.
  • File consumer complaint if no resolution within a reasonable time.
  • Keep copies of all correspondence and recall notices.

How to prevent similar issues

  • Require CGMP-compliant suppliers for compounding drugs.
  • Verify endotoxin testing and batch validation before distribution.
  • Keep batch numbers and NDCs for future recalls.

Documentation advice

Save recall notice, batch numbers, manufacturer contact, and medical records if exposure occurs.

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

Product: Semaglutide for Rx compounding use only. Packaging sizes and NDCs: 1 g (84385-106-01); 5 g (84385-106-02); 10 g (84385-106-06); 25 g (84385-106-03); 50 g (84385-106-04); 100 g (84385-106-05). Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China. Distribution: Nationwide in the United States. Recall Date: 2026-02-13. Report Date: 2026-03-11. Classification: Class II. Quantity: N/A.

Key Facts

  • 6 packaging sizes recalled: 1 g, 5 g, 10 g, 25 g, 50 g, 100 g
  • Mfg Date: Sep 25, 2025
  • Retest Date: Sep 24, 2027
  • Recall date: 2026-02-13; Report date: 2026-03-11; Status: Active

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
7/ 10
Affected Groups
GENERAL
Injury Types
POISONINGOTHER

Product Details

Model Numbers
Batch CP-030-20250911
Mfg Date: Sep 25, 2025
Retest Date: Sep 24, 2027
2025
2027
Affected States
ALL
Report Date
March 11, 2026
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Health & Personal Care
MEDIUM

AvKARE Recalls Rosuvastatin Tablets Due to Dissolution Issues

AvKARE recalled 7,991 cartons of Rosuvastatin Tablets on December 31, 2025. The recall stems from the product being out of specification for dissolution. Consumers should stop using the medication immediately and consult healthcare providers for guidance.

LACTATED RINGERS
Presence of
Read more